Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

Michelle SamuelJean Claude TardifPaul KhairyFrançois RoubilleDavid D WatersJean C GrégoireFausto J PintoAldo P MaggioniRafael DiazColin BerryWolfgang KoenigPetr OstadalJose Lopez-SendonHabib GamraGhassan S KiwanMarie-Pierre DubéMylène ProvencherAndreas OrfanosLucie BlondeauSimon KouzPhilippe L L'AllierReda IbrahimNadia BouabdallaouiDominic MitchellMarie-Claude GuertinJacques Lelorier

Published in: European heart journal. Quality of care & clinical outcomes (2022)

Cost-effectiveness analyses indicate that the addition of colchicine to standard-of-care therapy after MI is economically dominant and therefore generates cost savings.

Keyphrases

low dose
healthcare
palliative care
study protocol
high dose
clinical trial
quality improvement
randomized controlled trial
phase ii
mesenchymal stem cells
affordable care act